MRAP and metabolic disease: Further in vivo evidence from animal studies, along with Genome Wide Association Studies (GWAS), pointed out that most of the identified novel GPCR partners interacting with MRAP1 or MRAP2 may have relevance to energy homeostasis and deficiency of which could lead to metabolic disorders and other neuronal related diseases (Table S1).